Document Type : Review


1 Rheumatology Rehabilitation Clinic, Musculoskeletal Medicine and Interventional Physiatry Division, Department of Physical Medicine and Rehabilitation, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

2 Department of Dental Radiology (Deputed in Anatomy Department) Shaheed Suhrawardy Medical College, Dhaka, Bangladesh

3 Department of Physical Medicine and Rehabilitation, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

4 Department of Paediatrics, Combined Military Hospital, Dhaka Cantonment, Dhaka, Bangladesh

5 Department of Physical Medicine and Rehabilitation Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

6 Office of the Vice Chancellor Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

7 NeuroRehabilitation, East Kent Hospital University, Canterbury,

8 Department of Pharmacology, CARe Medical College, Dhaka, Bangladesh

9 Department of Rheumatology (Online Program), University of South Wales CF37 1DL Pontypridd Cardiff, UK.



Literature described wide disparities in incidence and prevalence between different types of vasculitis. There were no comprehensive studies on ethnic or racial associations in all types of primary systemic vasculitis (PSV) in any published article until this review commenced in 2020. The review aims to synthesize the evidence regarding the relation between ethnicity and the incidence and/or prevalence of different types of PSV. A total of 52 selected articles which include clinical trials, cohorts, cross-sectional studies, case series, and case studies and have been published within the last 10 years in the human population, were reviewed by searching Medline, PubMed, and Google Scholars databases using predefined keywords. The PRISMA diagrams were followed to identify relevant articles. The methodological qualities of the studies were assessed using the EPHPP tool. Finally, a summary of the evidence on the association between ethnic origin and PSV was painstakingly compiled. The connection between ethnicity and different types of PSV has been found to be significantly diverse in this researchas vasculitis is more common in Asians and Scandinavians, Kawasaki disease and periarteritis nodules are more prevalent in Japanese and Alaskanatives,ANCAassociated vasculitis is more frequent in Caucasians, whereas Henoch-Schonleinpurpura and Cogan syndrome more usual in Caucasians and Asians. Furthermore, Behçet's disease more commonly occurs on the "Silk Road," especially in Turkey. Genetic susceptibility and environmental elements could contribute to the global variation in the incidence and prevalence of primary systemic vasculitis.


Main Subjects

  1. Bijlsma J. EULAR Textbook On Rheumatic Diseases. 1st ed. London: BMJ Publishing Group. 2013: 616-636.
  2. Types of Vasculitis: Johns Hopkins Vasculitis Center. Johns Hopkins Vasculitis Center. 2022. (Accessed 29 October 2022).
  3. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism. 2012;65(1):1–11.
  4. van der Geest KSM, Sandovici M, van Sleen Y, Sanders J-S, Bos NA, Abdulahad WH, Stegeman CA, Heeringa P, et al. Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? Arthritis & Rheumatology. 2018;70(9):1366–1376.
  5. Imai N, Kuroda R, Konishi T, Serizawa M, Kobari M. Giant Cell Arteritis: Clinical Features of Patients Visiting a Headache Clinic in Japan. Internal Medicine. 2011;50(16):1679–1682.
  6. Crow RW, Katz BJ, Warner JEA, Alder SC, Zhang K, Schulman S, Digre KB. Giant Cell Arteritis and Mortality. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2009;64A(3):365–369.
  7. Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn J-E, Benhamou Y, Chiche L, Koskas F, Cluzel P, Hachulla E, Messas E, Resche-Rigon M, Cacoub P, Mirault T, et al. Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis. Circulation. 2017;136(12):1114–1122.
  8. Russo RAG, Katsicas MM. Takayasu Arteritis. Frontiers in Pediatrics. 2018;6.
  9. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation. 2017;135(17).
  10. Dietz SM, van Stijn D, Burgner D, Levin M, Kuipers IM, Hutten BA, Kuijpers TW. Dissecting Kawasaki disease: a state-of-the-art review. European Journal of Pediatrics. 2017;176(8):995–1009.
  11. Hoang MP, Park J. Vasculitis. Hospital-Based Dermatopathology. 2020:245–296.
  12. Sreih AG, Annapureddy N, Springer J, Casey G, Byram K, Cruz A, et al. Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases. Pharmacoepidemiology and Drug Safety. 2016;25(12):1368–1374.
  13. Demirkaya E, Arici ZS, Romano M, Berard RA, Aksentijevich I. Current State of Precision Medicine in Primary Systemic Vasculitides. Frontiers in Immunology. 2019;10.
  14. Bonatti F, Reina M, Neri TM, Martorana D. Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art. Frontiers in Immunology. 2014;5:1-14.
  15. Brogan P, Eleftheriou D. Vasculitis update: pathogenesis and biomarkers. Pediatric Nephrology. 2017;33(2):187–198.
  16. Piram M, Maldini C, Mahr A. Effect of race/ethnicity on risk, presentation, and course of connective tissue diseases and primary systemic vasculitides. Current Opinion in Rheumatology. 2012;24(2):193–200.
  17. Katsuyama T, Sada K-E, Makino H. Current Concept and Epidemiology of Systemic Vasculitides. Allergology International. 2014;63(4):505–513.
  18. Pearce FA, Craven A, Merkel PA, Luqmani RA, Watts RA. Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody–associated vasculitis. Rheumatology. 2017;56(11):1962–1969.
  19. Berti A, Dejaco C. Update on the epidemiology, risk factors, and outcomes of systemic vasculitides. Best Practice & Research Clinical Rheumatology. 2018;32(2):271–294.
  20. Nair AM, Goel R, Hindhumati M, Shah K, Chandana P, Jayaseelan V, et al. C-reactive protein gene polymorphisms (rs1205) in Asian Indian patients with Takayasu arteritis: Associations and phenotype correlations. International Journal of Rheumatic Diseases. 2017;21(3):732–739.
  21. Takamura C, Ohhigashi H, Ebana Y, Isobe M. New Human Leukocyte Antigen Risk Allele in Japanese Patients With Takayasu Arteritis. Circulation Journal. 2012;76(7):1697–1702.
  22. Terao C, Yoshifuji H, Kimura A, Matsumura T, Ohmura K, Takahashi M, et al. Two Susceptibility Loci to Takayasu Arteritis Reveal a Synergistic Role of the IL12B and HLA-B Regions in a Japanese Population. The American Journal of Human Genetics. 2013;93(2):289–297.
  23. Gudbrandsson B, Molberg Ø, Garen T, Palm Ø. Prevalence, Incidence, and Disease Characteristics of Takayasu Arteritis by Ethnic Background: Data From a Large, Population-Based Cohort Resident in Southern Norway. Arthritis Care & Research. 2016;69(2):278–285.
  24. Bilge NSY, Kaşifoğlu T, Cansu DÜ, Korkmaz C. Retrospective evaluation of 22 patients with Takayasu's arteritis. Rheumatology International. 2011;32(5):1155–1159.
  25. Gruener AM, Poostchi A, Carey AR, Eberhart CG, Henderson AD, Chang JR, McCulley TJ. Association of Giant Cell Arteritis with Race. JAMA Ophthalmology. 2019;137(10):1175.
  26. Brekke LK, Diamantopoulos AP, Fevang B-T, Aβmus J, Esperø E, Gjesdal CG. Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study. Arthritis Research & Therapy. 2017;19(1).
  27. Tan N, Acheson J, Ali N. Giant cell arteritis in patients of Indian Subcontinental descent in the UK. Eye. 2018;33(3):459–463.
  28. Pereira LS, Yoon MK, Hwang TN, Hong JE, Ray K, Porco T, McCulley TJ. Giant cell arteritis in Asians: a comparative study. British Journal of Ophthalmology. 2010;95(2):214–216.
  29. Wang Y, Lu Z, Fu L, Tan Y, Che D, Huang P, Pi L, Xu Y, Liang Q, Zhang L, Qiu X, Gu X. The miRNA-608 rs4919510 G>C polymorphism confers reduce coronary injury of Kawasaki disease in a Southern Chinese population. Bioscience Reports. 2019;39(5):1-7.
  30. Kuo H-C, Onouchi Y, Hsu Y-W, Chen W-C, Huang J-D, Huang Y-H, Yang Y-L, Chao M-C, Yu H-R, Juan Y-S, Kuo C-M, Yang KD, Huang J-S, Chang W-C. Polymorphisms of transforming growth factor-β signaling pathway and Kawasaki disease in the Taiwanese population. Journal of Human Genetics. 2011;56(12):840–845.
  31. Yeter D, Portman M, Aschner M, Farina M, Chan W-C, Hsieh K-S, Kuo H-C. Ethnic Kawasaki Disease Risk Associated with Blood Mercury and Cadmium in U.S. Children. International Journal of Environmental Research and Public Health. 2016;13(1):101.
  32. Kim J, Shimizu C, Kingsmore SF, Veeraraghavan N, Levy E, Ribeiro dos Santos AM, Yang H, Flatley J, Hoang LT, Hibberd ML, Tremoulet AH, Harismendy O, Ohno-Machado L, Burns JC. Whole genome sequencing of an African American family highlights toll-like receptor 6 variants in Kawasaki disease susceptibility. Prokunina-Olsson L, ed. PLOS ONE. 2017;12(2):e0170977.
  33. Amano Y, Akazawa Y, Yasuda J, Yoshino K, Kojima K, Kobayashi N, Matsuzaki S, Nagasaki M, Kawai Y, Minegishi N, Ishida N, Motoki N, Hachiya A, Nakazawa Y, Yamamoto M, et al. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease. Pediatric Rheumatology. 2019;17(1).
  34. Nagelkerke SQ, Tacke CE, Breunis WB, Tanck MWT, Geissler J, Png E, et al. Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease. Frontiers in Immunology. 2019;10.185.
  35. Boudiaf H, Achir M. The Clinical Profile of Kawasaki Disease in Algerian Children: A Single Institution Experience. Journal of Tropical Pediatrics. 2015;62(2):139–143.
  36. Fernandez-Cooke E, Barrios Tascón A, Sánchez-Manubens J, Antón J, Grasa Lozano CD, Aracil Santos J, Villalobos Pinto E, Clemente Garulo D, Mercader Rodríguez B, Bustillo Alonso M, NuñezCuadros E, Navarro Gómez ML, Domínguez-Rodríguez S, Calvo C. Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group. Corsini I, ed. PLOS ONE. 2019;14(5):e0215665.
  37. Holman R, Christensen K, Belay E, Steiner C, Effler P, Miyamur J, Forbes S, Schonberger L, Melish M. Racial/Ethnic Differences in the Incidence of Kawasaki Syndrome among Children in Hawaii. Hawaii Medical Journal. 2010; 69(8): 194-197.
  38. Ghimire LV, Chou F-S, Mahotra NB, Sharma SP. An update on the epidemiology, length of stay, and cost of Kawasaki disease hospitalization in the United States. Cardiology in the Young. 2019;29(6):828–832.
  39. Manlhiot C, O'Shea S, Bernknopf B, LaBelle M, Chahal N, Dillenburg RF, Lai LS, Bock D, Lew B, Masood S, Mathew M, McCrindle BW. Epidemiology of Kawasaki Disease in Canada 2004 to 2014: Comparison of Surveillance Using Administrative Data vs Periodic Medical Record Review. Canadian Journal of Cardiology. 2018;34(3):303–309.
  40. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, Kotani K, Tsogzolbaatar E-O, Yanagawa H. Epidemiologic Features of Kawasaki Disease in Japan: Results of the 2009-2010 Nationwide Survey. Journal of Epidemiology. 2012;22(3):216–221.
  41. Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama Y, Kojo T, Uehara R, Kotani K, Yanagawa H. Descriptive Epidemiology of Kawasaki Disease in Japan, 2011-2012: From the Results of the 22nd Nationwide Survey. Journal of Epidemiology. 2015;25(3):239–245.
  42. Makino N, Nakamura Y, Yashiro M, Sano T, Ae R, Kosami K, Kojo T, Aoyama Y, Kotani K, Yanagawa H. Epidemiological observations of Kawasaki disease in Japan, 2013-2014. Pediatrics International. 2018;60(6):581–587.
  43. Park YW, Han JW, Hong YM, Ma JS, Cha SH, Kwon TC, Lee SB, Kim CH, Lee JS, Kim CH. Epidemiological features of Kawasaki disease in Korea, 2006-2008. Pediatrics International. 2011;53(1):36–39.
  44. Karadag O, Erden A, Bilginer Y, Gopaluni S, Sari A, Armagan B, Ertenli I, Ozen S, Jayne D. A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts. Rheumatology International. 2018;38(10):1833–1840.
  45. Jelusic M, Vikic-Topic M, Batinic D, Milosevic D, Malenica B, Malcic I. Polyarteritis nodosa in Croatian children: a retrospective study over the last 20 years. Rheumatology International. 2012;33(12):3087–3090.
  46. Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota. Arthritis & Rheumatology. 2017;69(12):2338–2350.
  47. Wu Z, Wu Q, Xu J, Chen S, Sun F, Li P, Bai Y, Zheng W, Chen H, Zhang F, Li Y. HLA-DPB1 variant rs3117242 is associated with anti-neutrophil cytoplasmic antibody-associated vasculitides in a Han Chinese population. International Journal of Rheumatic Diseases. 2015;20(8):1009–1015.
  48. Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DRW, Scott DGI, Hashimoto H, Nunoi H. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. Rheumatology. 2011;50(10):1916–1920.
  49. Cao Y, Schmitz JL, Yang J, Hogan SL, Bunch D, Hu Y, Jennette CE, Berg EA, Arnett FC, Jennette JC, Falk RJ, Preston GA. DRB1*15Allele Is a Risk Factor for PR3-ANCA Disease in African Americans. Journal of the American Society of Nephrology. 2011;22(6):1161–1167.
  50. Enkhmaa B, Anuurad E, Zhang W, Kim K, Berglund L. Diverging trajectory patterns of systemic versus vascular inflammation over age in healthy Caucasians and African-Americans. Atherosclerosis. 2015;239(2):509–515.
  51. Ahn JK, Hwang J-W, Lee J, Jeon CH, Cha H-S, Koh E-M. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatology International. 2011;32(10):2979–2986.
  52. Li J, Cui Z, Long J, Huang W, Wang J, Wang H, Zhang L, Chen M, Zhao M. The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China. Arthritis Research & Therapy. 2018;20(1).
  53. Faurschou M, Helleberg M, Obel N, Baslund B. Incidence of granulomatosis with polyangiitis (Wegener's) in Greenland and the Faroe Islands: epidemiology of an ANCA-associated vasculitic syndrome in two ethnically distinct populations in the North Atlantic area. Clin Exp Rheumatol. 2013; 31(75):S52-S55.
  54. Terrier B, Dechartres A, Deligny C, Godmer P, Charles P, Hayem G, et al. Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French population. Rheumatology. 2016:kew423.
  55. Nesher G, Ben-Chetrit E, Mazal B, Breuer GS. The Incidence of Primary Systemic Vasculitis in Jerusalem: A 20-year Hospital-based Retrospective Study. The Journal of Rheumatology. 2016;43(6):1072–1077.
  56. Wada T, Hara A, Arimura Y, Sada K-E, Makino H. Risk Factors Associated with Relapse in Japanese Patients with Microscopic Polyangiitis. The Journal of Rheumatology. 2011;39(3):545–551.
  57. Pearce FA, Lanyon PC, Grainge MJ, Shaunak R, Mahr A, Hubbard RB, Watts RA. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology. 2016;55(9):1656–1663.
  58. Ortiz-Fernández L, Montes-Cano M, García-Lozano J, Conde-Jaldón M, Ortego-Centeno N, González-Leon R, et al. PTPN22 is not associated with Behçet's disease. A study spanning the complete gene region in the Spanish population and meta-analysis of the functional variant R620W. Clinical and Experimental Rheumatology. 2016; 34(6):1-6.
  59. Saleh OA, Birnbaum AD, Tessler HH, Goldstein DA. Behçet Uveitis in the American Midwest. Ocular Immunology and Inflammation. 2012;20(1):12–17.
  60. Li H, Liu Q, Hou S, Du L, Zhou Q, Zhou Y, Kijlstra A, Li Z, Yang P. TNFAIP3 gene polymorphisms confer risk for Behcet's disease in a Chinese Han population. Human Genetics. 2012;132(3):293–300.
  61. Hou S, Qi J, Zhang Q, Liao D, Li Q, Hu K, Zhou Y, Kijlstra A, Yang P. Genetic variants in the JAK1 gene confer a higher risk of Behcet's disease with ocular involvement in Han Chinese. Human Genetics. 2013;132(9):1049–1058.
  62. Wu Z, Chen H, Sun F, Xu J, Zheng W, Li P, et al. PTPN2 rs1893217 single-nucleotide polymorphism is associated with risk of Behçet's disease in a Chinese Han population. Clin Exp Rheumatol. 2014;32(84):S20-S26.
  63. Bonyadi M, Gholizadeh M, Soltan-Ali M. MDR1C3435T polymorphism associated with the development of clinical features in Behçet's disease in Iranian Azeri Turkish patients. International Journal of Dermatology. 2014;53(10):1235–1240.
  64. Shahneh FZ, Babaloo Z, Baradaran B, Hamzavi F, Bayazi B, Bandehagh A. Behçet's Syndrome in Iranian Azari People. Pakistan Journal of Biological Sciences. 2012;15(21):1045–1047.
  65. Shi Y, Jia Y, Hou S, Fang J, Zhou Y, Kijlstra A, Yang P. Association of a TNIP1 Polymorphism with Vogt-Koyanagi-Harada Syndrome but Not with Ocular Behcet's Disease in Han Chinese. Anderson MG, ed. PLoS ONE. 2014;9(5):e95573.
  66. Li X, Bai L, Fang J, Hou S, Zhou Q, Yu H, Kijlstra A, Yang P. Genetic Variations of IL-12B, IL-12Rβ1, IL-12Rβ2 in Behcet's Disease and VKH Syndrome. Yao Y-G, ed. PLoS ONE. 2014;9(5):e98373.
  67. Montes-Cano M, Conde-Jaldón M, García-Lozano J, Ortiz-Fernández L, Ortego-Centeno N, Castillo-Palma M, et al. HLA and non-HLA genes in Behçet's disease: a multicentric study in the Spanish population. Arthritis Research & Therapy. 2013;15(5):R145.
  68. Savey L, Resche-Rigon M, Wechsler B, Comarmond C, Piette JC, Cacoub P, Saadoun D. Ethnicity and association with disease manifestations and mortality in Behçet's disease. Orphanet Journal of Rare Diseases. 2014;9(42):1-7.
  69. Jiang Y, Wang H, Yu H, Li L, Xu D, Hou S, Kijlstra A, Yang P. Two Genetic Variations in the IRF8 region are associated with Behçet's disease in Han Chinese. Scientific Reports. 2016;6(1).
  70. Kawasaki Y, Suyama K, Yugeta E, Katayose M, Suzuki S, Sakuma H, Nemoto K, Tsukagoshi A, Nagasawa K, Hosoya M. The incidence and severity of Henoch-Schönlein purpura nephritis over a 22-year period in Fukushima Prefecture, Japan. International Urology and Nephrology. 2010;42(4):1023–1029.
  71. Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: New classification. International Journal of Cardiology. 1996;54:S155–S163.
  72. Espinoza J, Ai S, Matsumura I. New Insights on the Pathogenesis of Takayasu Arteritis: Revisiting the Microbial Theory. Pathogens. 2018;7(3):73.
  73. Grayson P, Ponte C, Suppiah R, Robson JC, Bates Gribbons K, Judge A et al. American College of Rheumatology-EULAR Classification Criteria for Takayasu's Arteritis. Arthritis and Rheumatology. 2022;7:2-23.
  74. Borchers AT, Gershwin ME. Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology, and treatment. Autoimmunity Reviews. 2012;11(6–7):A544–A554.
  75. Ninan J, Lester S, Hill C. Giant cell arteritis. Best Practice & Research Clinical Rheumatology. 2016;30(1):169–188.
  76. González-Gay MÁ, Ortego-Jurado M, Ercole L, Ortego-Centeno N. Giant cell arteritis: is the clinical spectrum of the disease changing? BMC Geriatrics. 2019;19(1).
  77. De Smit E, Clarke L, Sanfilippo PG, Merriman TR, Brown MA, Hill CL, Hewitt AW. Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence? RMD Open. 2017;3(2):e000531.
  78. Richards BL, March L, Gabriel SE. Epidemiology of large-vessel vasculidities. Best Practice & Research Clinical Rheumatology. 2010;24(6):871–883.
  79. Li L, Neogi T, Jick S. Mortality in Patients with Giant Cell Arteritis: A Cohort Study in UK Primary Care. Arthritis Care & Research. 2018;70(8):1251–1256.
  80. Monach PA, Merkel PA. Genetics of vasculitis. Current Opinion in Rheumatology. 2010;22(2):157–163.
  81. Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatric Nephrology. 2009;25(9):1641–1652.
  82. Bae YD, Choi HJ, Lee JC, Park JJ, Lee YJ, Lee EB, Song YW. Clinical Features of Polyarteritis Nodosa in Korea. Journal of Korean Medical Science. 2006;21(4):591.
  83. Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, Watts R, Merkel PA, Luqmani RA. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clinical and Experimental Nephrology. 2013;17(5):619–621.
  84. Jacobs-Kosmin D. Polyarteritis Nodosa: Practice Essentials, Pathophysiology, Etiology. Polyarteritis Nodosa: Practice Essentials, Pathophysiology, Etiology. 2022.
  85. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: A capture-recapture estimate. Arthritis Care & Research. 2004;51(1):92–99.
  86. Kanecki K, Nitsch-Osuch A, Gorynski P, Wierzba W, Tarka P, Tyszko P. Polyarteritis nodosa: decreasing incidence in Poland. Archives of Medical Science. 2019;15(5):1308–1312.
  87. Eleftheriou D, Dillon MJ, Tullus K, Marks SD, Pilkington CA, Roebuck DJ, Klein NJ, Brogan PA. Systemic Polyarteritis Nodosa in the Young: A Single‐Center Experience Over Thirty‐Two Years. Arthritis & Rheumatism. 2013;65(9):2476–2485.
  88. Yalçınkaya F, Özçakar ZB, Kasapçopur Ö, Öztürk A, Akar N, Bakkaloğlu A, Arısoy N, Ekı̇m M, Özen S. Prevalence of the MEFV Gene Mutations in Childhood Polyarteritis Nodosa. The Journal of Pediatrics. 2007;151(6):675–678.
  89. Burns JC. History of the worldwide emergence of Kawasaki disease. International Journal of Rheumatic Diseases. 2017;21(1):13–15.
  90. AL-Ammouri I, Al-Wahsh S, Khuri-Bulos N. Kawasaki disease in Jordan: demographics, presentation, and outcome. Cardiology in the Young. 2011;22(4):390–395.
  91. Guo MM-H, Tseng W-N, Ko C-H, Pan H-M, Hsieh K-S, Kuo H-C. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy. 2015;70(3):310–318.
  92. Chahal N, Somji Z, Manlhiot C, Clarizia NA, Ashley J, Yeung RSM, McCrindle BW. Rate, associated factors, and outcomes of recurrence of Kawasaki disease in Ontario, Canada. Pediatrics International. 2012;54(3):383–387.
  93. Ball G. The History of ANCA-associated Vasculitis. Rheumatic Disease Clinics of North America. 2010;36(3):439-446.
  94. WATTS RA. Epidemiology of vasculitis in Europe. Annals of the Rheumatic Diseases. 2001;60(12):1156a–11157.
  95. Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suárez LF. Classification, epidemiology, and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrology Dialysis Transplantation. 2015;30(suppl_1):i14–i22.
  96. Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. Rheumatology. 2020;59(Supplement_3):iii42–iii50.
  97. Sugiyama K, Sada K, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clinical and Experimental Nephrology. 2012;17(1):51–58.
  98. Ugarte-Gil M, Espinoza L. 2014. Genetics of ANCA-associated Vasculitides. Current Rheumatology Reports. 2014;16(7):428.
  99. Panupattanapong S, Stwalley DL, White AJ, Olsen MA, French AR, Hartman ME. Epidemiology and Outcomes of Granulomatosis with Polyangiitis in Pediatric and Working‐Age Adult Populations In the United States. Arthritis & Rheumatology. 2018;70(12):2067–2076.
  100. Oni L, Sampath S. Childhood IgA Vasculitis (Henoch Schonlein Purpura)—Advances and Knowledge Gaps. Frontiers in Pediatrics. 2019;7.
  101. Yagnik P, Jain A, Amponsah JK, Bhatt P, Parmar N, Donda K, Sharma M, Dave M, Chaudhari R, Vasylyeva TL, Dapaah-Siakwan F. National Trends in the Epidemiology and Resource Use for Henoch-Schönlein Purpura (IgA Vasculitis) Hospitalizations in the United States From 2006 to 2014. Hospital Pediatrics. 2019;9(11):888–896.
  102. López-Mejías R, Castañeda S, Genre F, Remuzgo-Martínez S, Carmona FD, Llorca J, Blanco R, Martín J, González-Gay MA. Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): An updated review. Autoimmunity Reviews. 2018;17(3):301–315.
  103. McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clinical Journal of the American Society of Nephrology. 2017;12(7):1162–1172.
  104. Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: An update in 2019. Joint Bone Spine. 2019;86(6):707–713.
  105. Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, Zignego AL, Ferri C. Cryoglobulinaemia. Nature Reviews Disease Primers. 2018;4(1).
  106. Zignego AL, Wojcik GL, Cacoub P, Visentini M, Casato M, Mangia A, Latanich R, Charles ED, Gragnani L, Terrier B, Piazzola V, Dustin LB, Khakoo SI, Busch MP, Lauer GM, et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes & Immunity. 2014;15(7):500–505.
  107. Sjöwall C, Mandl T, Skattum L, Olsson M, Mohammad AJ. Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology. 2018;57(8):1400–1407.
  108. Kirino Y, Nakajima H. Clinical and Genetic Aspects of Behçet's Disease in Japan. Internal Medicine. 2019;58(9):1199–1207.
  109. Salmaninejad A, Gowhari A, Hosseini S, Aslani S, Yousefi M, Bahrami T, Ebrahimi M, Nesaei A, Zal M. Genetics and immunodysfunction underlying Behçet's disease and immunomodulant treatment approaches. Journal of Immunotoxicology. 2017;14(1):137–151.
  110. Bonaguri C, Orsoni J, Russo A, Rubino P, Bacciu S, Lippi G, Melegari A, Zavota L, Ghirardini S, Mora P. Cogan's syndrome: anti-Hsp70 antibodies are a serological marker in the typical form. Isr Med Assoc J. 2014;16(5):285-288.
  111. Cogan's Syndrome - Vasculitis Foundation. Vasculitis Foundation. 2022.[Accessed 29 October 2022].
  112. Iliescu DA, Timaru CM, Batras M, De Simone A, Stefan C. COGAN'S SYNDROME. Rom J Ophthalmol. 2015;59(1):6-13.
  113. Atisha-Fregoso Y, Hinojosa-Azaola A, Alcocer-Varela J. Localized, single-organ vasculitis: clinical presentation and management. Clinical Rheumatology. 2013; 32:1-6.